Novo Nordisk Stock Plunges 13% as Weight-Loss Drug Trails Eli Lilly Rival

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Novo Nordisk Shares Plunge 13% as Weight-Loss Drug Fails to Match Eli Lilly Rival

Novo Nordisk

C

CNBC TV18•23-02-2026, 16:24

Novo Nordisk Shares Plunge 13% as Weight-Loss Drug Fails to Match Eli Lilly Rival

•Novo Nordisk's experimental obesity drug CagriSema did not achieve non-inferiority in weight loss compared to Eli Lilly's tirzepatide.
•CagriSema patients recorded 23% weight loss, falling short of tirzepatide's 25.5% after 84 weeks.
•Novo Nordisk shares tumbled over 13% in pre-market trading, hitting their lowest since July 2021.
•Eli Lilly's shares rose 3.5% in US pre-market dealings following the news.
•Novo plans further trials and higher-dose combinations for CagriSema amidst intensifying competition in the obesity drug market.

Read Full Article on Cnbc in English

✦

More like this

✦

More like this

Q3 Results impact on LIC, Kaynes Tech shares

LIC Soars 8% on Strong Q3 Results, Kaynes Tech Falls as Profit Misses Estimates

Three other companies whose lock-ins end this week include Sudeep Pharma, worth ₹153.6 crore on Tuesday, February 24, and whose shares are still above their issue price, Shreeji Shipping on Wednesday, February 25, where shares worth nearly ₹420 crore will free up for trade. That stock too trades above its issue price, and Patel Retail on Wednesday, February 25, whose shares worth ₹316 crore will free up for trade. Patel Retail shares currently trade below their issue price.

Markets Log Third-Worst Weekly Fall of 2026; Nifty IT Plunges 19% in February

Novo Nordisk

Novo Nordisk Sues Hims & Hers Over Weight-Loss Pill, Shares React

Broader markets decline

Small, Midcap Stocks Plunge Up To 5% Amid Market Weakness: Top Losers Revealed

Investors Buy Dip Amid US-Iran Tensions; JPMorgan Cautious Despite Market Rebound

Investors Buy Dip Amid US-Iran Tensions; JPMorgan Cautious Despite Market Rebound

Market Crashes Second Week Amidst West Asia Tensions; Nifty Bank Sees 14-Month Low

Market Crashes Second Week Amidst West Asia Tensions; Nifty Bank Sees 14-Month Low